{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:15:27Z","timestamp":1720829727585},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"DOI":"10.1007\/s00393-023-01316-7","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T01:31:13Z","timestamp":1675992673000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DMARD(\u201edisease-modifying antirheumatic drug\u201c)-Therapie bei fr\u00fcherer und aktiver Tumorerkrankung","DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer"],"prefix":"10.1007","author":[{"given":"Klaus","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"1316_CR1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon\u00a0TA, Thompson\u00a0A, Gandhi\u00a0KK et al (2015) Incidence of malignancy in adult patients with rheumatoid arthritis: a\u00a0meta-analysis. Arthritis Res Ther 17:212","journal-title":"Arthritis Res Ther"},{"key":"1316_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4609486","author":"S Raheel","year":"2016","unstructured":"Raheel\u00a0S, Crowson\u00a0CS, Wright\u00a0K et al (2016) Risk of malignant neoplasm in patients with incident rheumatoid arthritis 1980\u20132007 in relation to a comparator cohort: a population-based study. Int J Rheumatol. https:\/\/doi.org\/10.1155\/2016\/4609486","journal-title":"Int J Rheumatol"},{"key":"1316_CR3","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/art.23716","volume":"59","author":"R Buchbinder","year":"2008","unstructured":"Buchbinder\u00a0R, Barber\u00a0M, Heuzenroeder\u00a0L et\u00a0al (2008) Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 59:794\u2013799","journal-title":"Arthritis Rheum"},{"key":"1316_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/0046-8177(94)90295-X","volume":"25","author":"OW Kamel","year":"1994","unstructured":"Kamel\u00a0OW, van de Rijn\u00a0M, LeBrun\u00a0DP et al (1994) Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 25:638\u2013643","journal-title":"Hum Pathol"},{"key":"1316_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0049-0172(99)80026-2","volume":"29","author":"P Beauparlant","year":"1999","unstructured":"Beauparlant\u00a0P, Papp\u00a0K, Haraoui\u00a0B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148\u2013158","journal-title":"Semin Arthritis Rheum"},{"key":"1316_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","volume":"158","author":"W Wang","year":"2018","unstructured":"Wang\u00a0W, Zhou\u00a0H, Liu\u00a0L (2018) Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem 158:502\u2013516","journal-title":"Eur J Med Chem"},{"key":"1316_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7326\/M19-3369","volume":"172","author":"DH Solomon","year":"2020","unstructured":"Solomon\u00a0DH, Glynn\u00a0RJ, Karlson\u00a0EW et al (2020) Adverse effects of low-dose methotrexate. A randomized trial. Ann Intern Med 172:369\u2013380","journal-title":"Ann Intern Med"},{"key":"1316_CR8","first-page":"146","volume":"50","author":"A Strangfeld","year":"2011","unstructured":"Strangfeld\u00a0A, Hyrich\u00a0K, Askling\u00a0J et\u00a0al (2011) Detection and evaluation of a\u00a0drug safety signal concerning pancreatic cancer: lessons from a\u00a0joint approach of three European biologics registers. Baillieres Clin Rheumatol 50:146\u2013151","journal-title":"Baillieres Clin Rheumatol"},{"key":"1316_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archinternmed.2007.107","volume":"168","author":"S Bernatsky","year":"2008","unstructured":"Bernatsky\u00a0S, Clarke\u00a0AE, Suissa\u00a0S (2008) Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168:378\u2013381","journal-title":"Arch Intern Med"},{"key":"1316_CR10","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/ard.2004.033241","volume":"64","author":"J Askling","year":"2005","unstructured":"Askling\u00a0J, Fored\u00a0CM, Baecklund\u00a0E et\u00a0al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414\u20131420","journal-title":"Ann Rheum Dis"},{"key":"1316_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semcancer.2013.12.001","volume":"24","author":"E Baecklund","year":"2014","unstructured":"Baecklund\u00a0E, Smedby\u00a0KE, Sutton\u00a0LA et\u00a0al (2014) Lymphoma development in patients with autoimmune and inflammatory disorders\u2014what are the driving forces? Semin Cancer Biol 24:61\u201370","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"1316_CR12","doi-asserted-by":"publisher","first-page":"e002139","DOI":"10.1136\/rmdopen-2021-002139","volume":"8","author":"R Seror","year":"2022","unstructured":"Seror\u00a0R, Lafourcade\u00a0A, De Rycke\u00a0Y et\u00a0al (2022) Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database. RMD Open 8(2):e2139","journal-title":"RMD Open"},{"key":"1316_CR13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette\u00a0X, Matucci-Cerinic\u00a0M, Pavelka\u00a0K et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a\u00a0systematic review and meta-analysis. Ann Rheum Dis 70:1895\u20131904","journal-title":"Ann Rheum Dis"},{"key":"1316_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rdc.2016.09.006","volume":"43","author":"R Seror","year":"2017","unstructured":"Seror\u00a0R, Mariette\u00a0X (2017) Malignancy and the risks of biologic therapies. Current status. Rheum Dis Clin North Am 43:43\u201364","journal-title":"Rheum Dis Clin North Am"},{"key":"1316_CR15","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","volume":"76","author":"LK Mercer","year":"2017","unstructured":"Mercer\u00a0LK, Regierer\u00a0AC, Mariette\u00a0X et\u00a0al (2017) Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a\u00a0European registries collaborative project. Ann Rheum Dis 76:2025\u20132030","journal-title":"Ann Rheum Dis"},{"key":"1316_CR16","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","volume":"127","author":"TL Michaud","year":"2014","unstructured":"Michaud\u00a0TL, Rho\u00a0YH, Shamlyan\u00a0T et al (2014) The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med 127:1208\u20131232","journal-title":"Am J Med"},{"key":"1316_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1136\/ard.2008.091025","volume":"68","author":"JP Leombruno","year":"2009","unstructured":"Leombruno\u00a0JP, Einarson\u00a0TR, Keystone\u00a0EC (2009) The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68:1136\u20131145","journal-title":"Ann Rheum Dis"},{"key":"1316_CR18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","volume":"74","author":"LK Mercer","year":"2015","unstructured":"Mercer\u00a0LK, Lunt\u00a0M, Low\u00a0ALS et al (2015) Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 74:1087\u20131093","journal-title":"Ann Rheum Dis"},{"key":"1316_CR19","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/ar2904","volume":"12","author":"A Strangfeld","year":"2010","unstructured":"Strangfeld\u00a0A, Hierse\u00a0F, Rau\u00a0R et\u00a0al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5","journal-title":"Arthritis Res Ther"},{"key":"1316_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24784","author":"A Wetzman","year":"2021","unstructured":"Wetzman\u00a0A, Cedric\u00a0L, Gaujoux-Viala\u00a0C et al (2021) Risk of cancer after initiation of targeted therapies in patients with rheumatoid arthritis and a prior cancer: systematic review with meta-analysis. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.24784","journal-title":"Arthritis Care Res"},{"key":"1316_CR21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","volume":"79","author":"A Sepriano","year":"2020","unstructured":"Sepriano\u00a0A, Kerschbaumer\u00a0A, Smolen\u00a0JS et\u00a0al (2020) Safety of synthetic and biological DMARDs: a\u00a0systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 79:760\u2013770","journal-title":"Ann Rheum Dis"},{"key":"1316_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","volume":"47","author":"JR Maneiro","year":"2017","unstructured":"Maneiro\u00a0JR, Souto\u00a0A, Gomez-Reino\u00a0JJ (2017) Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Semin Arthritis Rheum 47:149\u2013156","journal-title":"Semin Arthritis Rheum"},{"key":"1316_CR23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","volume":"177","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m\u00a0H, Frisell\u00a0T, Askling\u00a0J et\u00a0al (2017) Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice A nationwide cohort study from Sweden. JAMA Intern Med 177:1605\u20131612","journal-title":"JAMA Intern Med"},{"key":"1316_CR24","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","volume":"61","author":"V Huss","year":"2022","unstructured":"Huss\u00a0V, Bower\u00a0H, Wadstr\u00f6m\u00a0H et al (2022) Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology 61:1810\u20131818","journal-title":"Rheumatology"},{"key":"1316_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","volume":"50","author":"W Xie","year":"2020","unstructured":"Xie\u00a0W, Yang\u00a0X, Huang\u00a0H et al (2020) Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies. Semin Arthritis Rheum 50:930\u2013937","journal-title":"Semin Arthritis Rheum"},{"key":"1316_CR26","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","volume":"59","author":"S De Germay","year":"2020","unstructured":"De Germay\u00a0S, Bagheri\u00a0H, Despas\u00a0F et al (2020) Abatacept in rheumatoid arthritis and the risk of cancer: a\u00a0world observational post-marketing study. Rheumatology 59:2360\u20132367","journal-title":"Rheumatology"},{"key":"1316_CR27","doi-asserted-by":"publisher","first-page":"e001363","DOI":"10.1136\/rmdopen-2020-001363","volume":"6","author":"K Chatzidionysiou","year":"2020","unstructured":"Chatzidionysiou\u00a0K, Delcoigne\u00a0B, Frisell\u00a0T et\u00a0al (2020) How do we use biologics in rheumatoid arthritis patients with a\u00a0history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open 6:e1363","journal-title":"RMD Open"},{"key":"1316_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","volume":"95","author":"F Wang","year":"2020","unstructured":"Wang\u00a0F, Sun\u00a0L, Wang\u00a0S et al (2020) Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc 95:1404\u20131419","journal-title":"Mayo Clin Proc"},{"key":"1316_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13317-021-00153-5","volume":"12","author":"V Solipuram","year":"2021","unstructured":"Solipuram\u00a0V, Mohan\u00a0A, Patel\u00a0R, Ni\u00a0R (2021) Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a\u00a0systematic review and meta-analysis of randomized controlled trials. Auto Immun Highlights 12:8","journal-title":"Auto Immun Highlights"},{"key":"1316_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg\u00a0SR, Bhatt\u00a0DL, Mikuls\u00a0TR et\u00a0al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N\u00a0Engl J Med 386:316\u2013326","journal-title":"N Engl J Med"},{"key":"1316_CR31","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer\u00a0JM, Bingham\u00a0CO III, Cappelli\u00a0LC et al (2021) Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5\u2011year results from a\u00a0United States-based rheumatoid arthritis registry. ACR Open Rheumatol 3:173\u2013184","journal-title":"ACR Open Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01316-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01316-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:55:32Z","timestamp":1720774532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01316-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":31,"alternative-id":["1316"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01316-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"19 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Kr\u00fcger hat Honorare f\u00fcr Vortr\u00e4ge und Beratungen von folgenden Firmen erhalten: AbbVie, BMS, Celltrion, Hexal, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}